Competitor Analysis: Cancer Peptides
Competitor Analysis: Cancer Peptides
The Competitive Intelligence Report Cancer Peptides as of November 2014 provides a competitor analysis in the product portfolios and development pipeline of peptide therapeutics for treatment of cancer. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Therapeutic cancer peptide therapeutics in total represent a considerable market size of more than US$ 8 bln in the year 2013. Major cancer peptide products are of the classes of somatostatin analogs and agonists and antagonists of the gonadotropin releasing hormone (GnRH), but also of targeted cancer therapy including proteasome and HDAC inhibition.
The report provides a compilation of currently major marketed peptide cancer products and active projects in research and development for novel cancer peptides. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced
The Competitive Intelligence Report Cancer Peptides as of November 2014 provides a competitor analysis in the product portfolios and development pipeline of peptide therapeutics for treatment of cancer. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Therapeutic cancer peptide therapeutics in total represent a considerable market size of more than US$ 8 bln in the year 2013. Major cancer peptide products are of the classes of somatostatin analogs and agonists and antagonists of the gonadotropin releasing hormone (GnRH), but also of targeted cancer therapy including proteasome and HDAC inhibition.
The report provides a compilation of currently major marketed peptide cancer products and active projects in research and development for novel cancer peptides. Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Company
- Product Category
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced
- 2013 Sales of Major Cancer Peptides
- Somatostatin Analogs
- GnRH Analogs: Agonists
- GnRH Analogs: Antagonists
- Targeted Cancer Peptides: Proteasome Inhibition
- Targeted Cancer Peptides: HDAC Inhibition
- Cytotoxic, Cytostatic or Apoptotic Cancer Peptides
- Cancer Peptide-Drug Conjugates and Peptide Fusion Proteins
- Other Cancer Peptides
- Corporate Cancer Peptide R&D Pipelines
